GAITHERSBURG, Md., Dec. 20,
2023 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS
Biopharma" or the "Company") (NASDAQ: YS), a global
biopharmaceutical company, today announced that upon the receipt of
a notice from the Chairperson of the Board of Directors, it would
hold an extraordinary general meeting of shareholders will be
held at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry
Park, Daxing District, Beijing, the
People's Republic of China, on December 28, 2023 at
9:00 a.m., Beijing Time (GMT+8). The
proposals to be submitted for shareholders' approval at the
extraordinary general meeting are the removal of each of
Hui Shao, Bo
Tan, Ajit Shetty, Viren T
Mehta, Shaojing Tong and
Rachel Yu as a director of the
Company and the appointment of each of Nan
Zhang, Yun Zhang,
Lui Chi Keung and Jingxian Li as a director of the Company.
December 20, 2023 has been fixed as
the record date (the "Record Date") for determining the
shareholders entitled to receive notice of the extraordinary
general meeting or any adjournment or postponement thereof. Holders
of record of the Company's ordinary shares at the close of business
on the Record Date are entitled to attend the extraordinary general
meeting and any adjournment or postponement thereof.
About YS Biopharma Co., Ltd.
YS Biopharma is a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and delivering new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary
PIKA® immunomodulating technology platform and a new
generation of preventive and therapeutic biologics targeting
Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other
virus infections. YS Biopharma operates in China, the United
States, Singapore, and
the Philippines, and is led by a
management team that combines rich local expertise and global
experience in the biopharmaceutical industry. For more information,
please visit investor.ysbiopharm.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
terminology such as "may," "will," "expect," "anticipate," "aim,"
"estimate," "intend," "plan," "believe," "potential," "continue,"
"is/are likely to" or other similar expressions. Such statements
are based upon management's current expectations and current market
and operating conditions and relate to events that involve known or
unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond the Company's
control, which may cause the Company's actual results, performance
or achievements to differ materially from those in the
forward-looking statements. Further information regarding these and
other risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. The
Company does not undertake any obligation to update any
forward-looking statement as a result of new information, future
events or otherwise, except as required under law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-co-ltd-to-hold-extraordinary-general-meeting-on-december-28-2023-302020111.html
SOURCE YS Biopharma
